Ascendis Pharma (ASND) CFO lists warrants, RSUs and shares

NodeGuardian · 2026-04-06T13:05:49+00:00

Scott Thomas Smith, EVP and CFO of Ascendis Pharma, filed an initial ownership statement revealing his holdings, which include multiple tranches of vested warrants, RSUs vesting in 2027, and direct ownership of 2,517 shares.

NodeGuardian

2026-04-06 13:05:49

Abstract generation in progress

Ascendis Pharma’s EVP and CFO, Scott Thomas Smith, has filed an initial statement of beneficial ownership (Form 3) revealing his holdings in the company. The filing details multiple tranches of fully vested and exercisable warrants with various exercise prices and expiration dates, as well as restricted stock units (RSUs) that begin vesting in March 2027. Smith also holds a direct ownership of 2,517 ordinary shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.